Vyrsa Technologies has an array of SI joint devices and was founded in 2021. It’s the only SI joint company with a complete portfolio of FDA-cleared sacroiliac joint fusion implants.
The deal was completed Nov. 30 and values Vyrsa at $40 million. Nevro will also pay up to an additional $35 million pending development and sales milestones.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.